ENGN vs ENSC

enGene Therapeutics Inc. vs Ensysce Biosciences, Inc. — Valuation Comparison 2026

ENGN

Biotechnology
enGene Therapeutics Inc.
Quality
4.1
out of 10
Value Trap
12
SAFE
Price
$1.78
Last close
Models
8/13
Active
VS

ENSC

Biotechnology
Ensysce Biosciences, Inc.
Quality
4.5
out of 10
Value Trap
33
LOW
Price
$0.30
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType ENGN Fair ValueENGN Upside ENSC Fair ValueENSC Upside
Bayesian DCF Intrinsic $0.58 -67.6% $0.11 -62.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.92 +8.1% $0.01 -97.0%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ENGN vs ENSC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ENGN vs ENSC — Which Stock Is More Undervalued?

ENSC scores higher with a 4.5/10 quality rating vs ENGN's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing enGene Therapeutics Inc. (ENGN) and Ensysce Biosciences, Inc. (ENSC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ENGN currently trades at $1.78 with a QOC of 4.1/10, while ENSC trades at $0.30 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).